Obesity biotech aims to reduce fat while preserving lean mass, with first-in-human studies planned for late 2027.
Seventy million dollars, an oversubscribed round and a mechanism that has nothing to do with appetite: Moonwalk Biosciences has just raised its Series B to press ahead with a rather different theory of obesity treatment. The company is developing adipose-targeted RNA interference (RNAi) therapies – siRNA medicines aimed squarely at fat tissue itself, rather than at the brain’s hunger signals – with lead candidate MW101 expected to enter first-in-human studies in late 2027. Alpha Wave and YK Bioventures co-led the round, with Eli Lilly and Gaorong Ventures joining existing backers ARCH Venture Partners, Khosla Ventures and Future Ventures.
The proposition behind MW101 is notably different from the appetite-centered mechanism that has come to dominate modern obesity medicine. Moonwalk is developing siRNA therapeutics designed to reach adipose tissue selectively, using proprietary targeting chemistry licensed exclusively from Suzhou Siran Biotechnology; its discovery platform combines human genetics, epigenomics and multi-omics to identify pathways involved in energy homeostasis, adipogenesis, lipolysis and thermogenesis. In preclinical studies, the company reports reductions in body weight and fat mass without reduced food intake, alongside preservation of lean mass; non-human primate studies have also shown durable adipose target engagement after a single dose.
Longevity.Technology: Obesity drug development is entering an interesting second act; once dramatic weight loss has become achievable, the more difficult question is what else a therapy can preserve, improve or simply leave alone. That makes Moonwalk’s proposition worth watching. An adipose-targeted RNAi therapy that reduces fat mass without suppressing appetite, preserves lean mass and potentially requires dosing only a few times a year would address several of the compromises that now sit rather awkwardly alongside the success of GLP-1 receptor agonists – but, for now, those advantages belong to preclinical models, not patients. The mechanistic logic is appealing: treat adipose tissue as the therapeutic destination rather than treating appetite as the route to it, and in doing so perhaps separate fat loss from the collateral loss of metabolically and functionally valuable muscle. Just as important, however, is the delivery question. Selective extrahepatic RNAi has been a stubborn technical problem; if Moonwalk’s adipose-targeting chemistry can reproduce in humans the tissue selectivity and durability seen in non-human primates, MW101 may prove interesting not merely as another entrant in an increasingly crowded obesity market, but as evidence that adipose itself can become a practical RNAi target. The human trial will therefore have rather more to establish than whether the scales move – body composition, tissue selectivity and durability will all matter, because in the post-GLP-1 era, losing weight is rapidly becoming the easy part; the harder question is what you can persuade the body to keep.
Beyond kilograms
The emphasis on lean mass reflects a broader change in the obesity field. GLP-1 receptor agonists have reset expectations around the magnitude of pharmacological weight loss; attention is now moving toward body composition, metabolic health and what happens to function alongside the falling number on the scale. For longevity medicine, the distinction is particularly pertinent – skeletal muscle is not expendable ballast, especially in older adults, and preserving it matters for strength, mobility and metabolic resilience. Longevity.Technology has previously highlighted the growing interest in therapies and treatment strategies that preserve muscle during obesity treatment.
Moonwalk CEO and cofounder Alex Aravanis told Longevity.Technology that the company believes its preclinical body-composition findings arise from acting directly on adipose rather than indirectly through appetite.
“Our approach is fundamentally different because MW101 is designed to act directly on adipose tissue rather than suppress appetite. In our preclinical studies, we’ve seen robust reductions in body weight and fat mass while preserving lean mass and without reducing food intake. We believe that reflects the ability to selectively modulate adipose biology while minimizing effects on other tissues.”
Whether that distinction survives first contact with human physiology is, of course, the important bit. Aravanis told us body composition would be studied as one measure among others, though Moonwalk is still finalizing the first-in-human trial and considers it premature to specify endpoints.
Getting RNAi out of the liver
The second challenge is less visible on the bathroom scales but potentially more consequential for the platform. RNAi therapeutics work by using small interfering RNA to silence selected gene expression; getting that molecular instruction to the intended tissue, however, is central to making the approach useful.
Moonwalk’s answer is its licensed adipose-targeting chemistry, designed to deliver siRNA selectively to fat while minimizing effects elsewhere. That tissue specificity could allow the company to manipulate metabolic pathways within adipose without relying on central appetite suppression; it also makes delivery itself an important part of MW101’s eventual clinical proof.
In non-human primates, Moonwalk says a single dose produced durable adipose target engagement, supporting the possibility of quarterly or even twice-yearly treatment. Those intervals remain possibilities rather than promises.
“Adipose-selective delivery is a key differentiator for Moonwalk,” Aravanis told Longevity.Technology. “We are using proprietary adipose-targeting chemistry exclusively licensed from Suzhou Siran Biotechnology for our pipeline, which enables siRNA to be delivered selectively to adipose tissue while minimizing effects on other tissues.”
The NHP data are encouraging, he added, but “the duration of effect and optimal dosing interval ultimately need to be established in humans.”
That translation will matter commercially as well as scientifically. A durable therapy administered several times a year would occupy a very different treatment niche from weekly injections; equally, a delivery technology capable of reliably reaching adipose could have utility across Moonwalk’s broader cardiometabolic pipeline, where the company is pursuing additional tissue-targeted siRNA programs.
Backing a different route
The Series B provides the capital to move MW101 through ongoing IND-enabling work and towards its planned 2027 clinical entry, while expanding the wider pipeline and discovery platform. For its investors, differentiation in a crowded obesity market appears central to the thesis.
“By targeting adipose tissue directly, Moonwalk may redefine how obesity is treated by delivering therapies with the potential for durable efficacy, lean muscle preservation and infrequent dosing,” said Rick Gerson, cofounder, Chairman and CEO of Alpha Wave Global.
All three remain to be demonstrated clinically. That is a substantial qualification, but also a useful description of what MW101 now has to prove.
Alongside the financing, Moonwalk has brought in Stephen Djedjos as Senior Vice President of Clinical Development – a hire that matters rather more than the average appointment note, given that he arrives from running clinical development on Kailera’s incretin obesity programs, with earlier stints at Gilead and Amgen, where he worked on Repatha. It is an appointment likely to prove to be useful insurance for a company about to run its first human trial of a genuinely new delivery mechanism.
What adipose can do
The first human study should begin to reveal whether adipose-selective RNAi can turn an elegant delivery concept into a useful metabolic intervention. If it can, the implications may reach beyond how much weight patients lose; adipose tissue could become a rather more precise therapeutic address, with obesity merely the first parcel through the door.
